TABLE 1.
Published clinical trials of stem cell therapies against COVID‐19
| Trial ID no. | Indications | Patient population | Source of cells | Dose of cells | Route | Frequency | Clinical phases | Reference |
|---|---|---|---|---|---|---|---|---|
| ChiCTR2000029990 a | Moderate/Severe/Critical | 7 | MSCs | 1 × 106 cells/kg/round | IV | 1 round | Phase I/II | 74 |
| NR | Severe/Critical | 25 | MSCs | 1 × 106 cells/kg/round | IV | 2 or 3 rounds (interval 5 d) | NR | 97 |
| NCT 03042143 b | ARDS | 60 | UC‐MSCs | 40 × 107 cells/round | IV | 1 round | Phase I/II | 112 |
| ChiCTR2000031319 NCT04336254 | Severe/Critical | 20 | DP‐MSCs | 3 × 107 cells/round | IV | 3 rounds at day 1, 4 and 7 | Phase I/II | 113 |
| NCT04331613 | ARDS | 2 | hESC‐IMRCs (CAStem) | 3, 5, 10 × 106 cells/kg/round | IV | 1 round | Phase I | 84 |
| NR | ARDS | 24 | BM‐MSCs‐EV | 15 mL | IV | 1 round | NR | 73 |
| NCT04348461 | Severe/Critical | 13 | AD‐MSCs | 1 × 106 cells/kg/round | IV | 1, 2 or 3 rounds | Phase II | 101 |
| ChiCTR2000029606 | ARDS | 2 | MB‐MSCs | NR | IV | 3 rounds | Not Applicable | 106 |
| ChiCTR2000031494 | Severe/Critical | 41 | UC‐MSCs | 2 × 106 cells/kg/round | IV | 1 round | Phase I | 98 |
| NR | Severe/Critical | 1 | UC‐MSCs | 5 × 107 cells/round | IV | 3 rounds (interval 3 d) | NR | 99 |
| NCT04288102 | Severe/Critical | 18 | UC‐MSCs | 3 × 107 cells/round | IV | 3 rounds (on days 0, 3 and 6) | Phase I | 100 |
Abbreviations: MSCs, mesenchymal stem cells; UC‐MSCs, umbilical cord‐derived MSCs; BM‐MSCs, bone marrow‐derived MSCs; AD‐MSCs, adipose‐derived MSCs; DP‐MSCs, dental pulp‐derived MSCs; BM‐MSCs‐EV, exosomes derived from bone marrow‐derived MSCs; IV, intravenous; MB‐MSCs, menstrual blood‐derived MSCs; hESC‐IMRCs, immunity‐ and matrix‐regulatory cells from human embryonic stem cells; NR, not reported.